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ABSTRACT
Objectives: This study was aimed to evaluate the
efﬁcacy and tolerability of bisoprolol, in Indian patients
diagnosed with stage I essential hypertension as ﬁrst-
line drug.
Design: This was an open-label, phase IV, multicentric
prospective study.
Settings: 239 outpatient centres across India.
Participants: After ethical approval, patients who were
willing to sign informed consent, who are newly
diagnosed with JNC VII stage I essential hypertension
(systolic blood pressure 140e159 mm Hg or diastolic
blood pressure 90e99 mm Hg) and who are
prescribed bisoprolol were enrolled in the study.
Patients with signiﬁcant organ disease or
complications, women of childbearing age refusing
reliable contraceptive method, patients with known
contraindications (like symptomatic bradycardia,
signiﬁcant atrioventricular blockade, sick sinus
syndrome) and patients with known hypersensitivity
reactions to bisoprolol and unwilling patients were
excluded.
Primary and secondary outcomes measures: The
primary outcome measure was percentage of patients
achieving blood pressure (BP) #140/90 mm Hg at the
end of 12 weeks, while multiple secondary outcome
measures were assessed.
Results: Of 2418 patients screened, 2161 patients
were recruited (66.64% men, mean age
51.769.8 years, smokers 19.19%) and 2131 (96.44%)
patients achieved BP control. There was signiﬁcant
reduction in systolic blood pressure ( 25.29; SD:
13.22 mm Hg), diastolic blood pressure ( 14.14; SD:
7.67 mm Hg) and heart rate ( 12/min; SD: 6.15)
compared with baseline (all p values <0.05). The
median dose of bisoprolol and average period required
for the response were 5 mg/day and 33 days,
respectively. Bisoprolol was found to be well tolerated
in the patients up to 10 mg/day. A total of 1.9%
patients showed adverse events, which were mild to
moderate in severity without any severe adverse event.
None required treatment withdrawal.
Conclusion: Bisoprolol is an effective and safe option
to control BP. Thus, it can be used as one of the ﬁrst-
line antihypertensive in Indian patients.
INTRODUCTION
Hypertension (HTN) is recognised as
a major risk factor for coronary, cerebral and
renal vascular disease.
1e4 It is estimated that
600 million people have HTN worldwide.
5 In
India, the prevalence of HTN is about 20%,
of whom 70% have stage I HTN.
6e8 HTN is
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ARTICLE SUMMARY
Article focus
- What is the efﬁcacy of bisoprolol in essential
hypertension patients?
- What is the average dose of bisoprolol required
for BP control?
- What is the tolerability of bisoprolol in essential
hypertensive patients?
Key messages
- Bisoprolol is safe and effective in stage I
essential hypertensive patients in India.
- The average dose required was 5 mg/day.
- Target BP was achieved in 96.44% patients.
Strengths and limitations of this study
- First-ever study done for bisoprolol in large
Indian population.
- Study re-afﬁrms bisoprolol as ﬁrst-line drug in
the management of hypertension.
- Open-label study.
- Short durationd3 months study.
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Open Access Researchresponsible for 57% and 24% of all stroke- and coronary
heart disease-related deaths, respectively.
9 There is
a need for increased awareness, diagnosis and manage-
ment of HTN.
Over the decades, b blockers were used as safe and
effective antihypertensives.
10e12 However, NICE-BSH
(National Institute of Clinical ExcellenceeBritish Society
of Hypertension, 2006) guidelines recommended that
b-adrenergic blockers are inferior to other classes of
drugs as ﬁrst-line antihypertensive and that combination
of diuretic and a b blocker may lead to precipitation of
diabetes. Most of the issues raised by NICE-BSH against
b blockers have been observed from less b-1 selective
blocker. On the contrary, Reappraisal of European
guidelines on hypertension management (2009)
suggested that all major antihypertensive drug
classes, that is, diuretics, ACE inhibitors, calcium antag-
onists, angiotensin receptor antagonists and b blockers
do not differ signiﬁcantly for their overall ability to
reduce blood pressure (BP) in HTN. They also
suggested that there is no undisputable evidence that
major drug classes differ in their ability to protect
against overall cardiovascular risk or cause-speciﬁc
cardiovascular events, such as stroke and myocardial
infarction.
13
b-2 Receptor blockade is responsible for various side
effects like impairment of glycaemic control, dyslipidemia
and erectile dysfunction. b-1 Selective b blockers are
effective among patients with natural (mostly younger
patients) or induced (smokers) high epinephrine or nor-
epinephrine levels.
14
Bisoprolol is widely studied in the management of
essential HTN worldwide. However, it remains to be
studied in Indian scenario. This study, BRIGHT (Biso-
prolol in Reaching Goals in Hypertension Trial), there-
fore, was aimed to assess the safety and efﬁcacy of
bisoprolol as the ﬁrst-line therapy against HTN in Indian
patients.
MATERIALS AND METHODS
Study design
BRIGHT was designed as an open-label, prospective,
multicentric phase IV study.
Ethical considerations
The study protocol was approved by either an Indepen-
dent Ethics Committee (for all the independent inves-
tigators) or Institutional Ethics Committees (for the
institutional sites). The study was conducted as per ICH
International Conference on Hormonization - Good
Clinical Practices (ICH GCP) guidelines 1996 and
Indian Council of Medical Research (ICMR) guidelines
for the ethical conduct of clinical research in human
beings, 2006. A written informed consent was obtained
from all the patients before the enrolment.
Study participants
Patients were enrolled from 239 centres across India
from May 2010 to July 2010. Those patients who are newly
diagnosed with stage I essential HTN as per JNC VII
criteria (systolic blood pressure (SBP) 140e159 mm Hg
or diastolic blood pressure (DBP) 90e99 mm Hg) and
those who were prescribed bisoprolol were enrolled in
this study. Patients unwilling to sign informed consent,
those with signiﬁcant organ disease, women of child-
bearing age refusing reliable contraceptive method,
those presenting with uncontrolled diabetes or diabetic
complications as well as those patients with known
contraindications, like symptomatic bradycardia, second-
or third-degree atrioventricular block, sick sinus
syndrome and those with known hypersensitivity reac-
tions to bisoprolol were excluded. Eligible patients were
prescribed bisoprolol at an escalating dose (bisoprolol in
India is available in four strengths, 1.25, 2.5, 5 and
10 mg). The investigators were suggested to start with
lower dose to improve tolerability and compliance
towards medication. There was no ﬁxed pattern
suggested for dose titration. If there was no adequate BP
control with given dose for 4 weeks, then dose was
doubled till 10 mg (target) or maximum tolerated dose
of bisoprolol. The demographic details and other base-
line measures such as cardiac parameters (heart rate
(HR), SBP and DBP), metabolic parameters (fasting
blood sugar levels, 2-h postprandial blood sugar level
and serum cholesterol levels), renal parameters (serum
creatinine, creatinine clearance from 24-h urine sample,
whenever it was indicated) and safety parameters
Table 1 Visit schedule
Visit V1 V2 V3 V4
Day Day 0 (baseline) Week 4 Week 8 Week 12
Informed consent X
Demographics and medical history X
Screening and inclusion/exclusion X
Physical examination X X X X
Dose titration X X
Vitals, blood pressure and heart rate X X X X
Investigations X X X
Concomitant medication X X X X
Adverse events X X X X
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Bisoprolol as initial therapy in hypertension(adverse events (AE)) were recorded. Risk factors like
smoking status (whether patient ever smoked or not)
were also collected. All the patients were regularly
followed on 4th, 8th and 12th week from the date of
enrolment (baseline visit). Any signiﬁcant ﬁndings in
physical examination, cardiac parameters and safety
parameters were noted during all the follow-up visits.
Metabolic and renal parameters were re-assessed at the
end of 4th and 12th weeks of treatment.
Efﬁcacy and tolerability evaluations
The primary end point, that is, the efﬁcacy of bisoprolol
was calculated by response rate. It was deﬁned as the
percentage of patients who achieved SBP #140 and DBP
#90 mm Hg at the end of 12 weeks treatment with
bisoprolol. The BP was recorded in the sitting position in
the right arm, with a standardised mercury sphygmo-
manometer after 5 min of rest. Similarly, HR was
measured in sitting position by measuring radial pulse
for 1 min after 5 min rest. The average reduction in the
SBP, DBP, average time to reach target BP (in
responders), median dose required to control (in
responders), average reduction in HR, assessment of
compliance at 12 weeks, blood glucose parameters, lipid
and renal parameter status from baseline to the end of
12 weeks were assessed as secondary end points. The
results for investigations were obtained from local labo-
ratories following the standard procedures. A patient was
considered as compliant if he/she consumed at least
80% of the tablets. Tolerability was assessed throughout
via AE reporting. The type of AE(s), number of AE(s)
and frequency of AE(s) were captured in the case record
form (table 1).
Compliance was also evaluated. With a dosing
schedule of one tablet per day, 84 (12 weeks) tablets
were to be consumed per patient for the overall study
period.
Statistical analysis
Descriptive statistics were used to summarise data. The
quantitative data were expressed as mean and SD.
Qualitative data were analysed by percentages or
proportions. Furthermore, to analyse the change in BP
and HR over the time, the data were analysed using the
analysis of variance followed by Dunnett’s post hoc
testing with baseline as control and paired t test. p Value
<0.05 was considered to be signiﬁcant.
RESULTS
Patient demography and baseline data
Of total 2418 patients screened, 257 patients were not
enrolled in the study either due to failure to meet the
inclusion criteria or due to refusal to give informed
consent. A total of 2161 patients were enrolled and
analysed in this study. The demographic and baseline
data of the patients are given in table 2.
Of all patients enrolled, 1440 (66.64%) were men and
430 (19.9%) were smokers. The response rates at the
end of 2nd week were 40.77%, and it increased by an
additional 26.19%, 17.82%, 11.66% during 4th, 8th, and
12th week, respectively. Thus, the response rate at
12 weeks was 96.44%. The mean SBP was signiﬁcantly
reduced from baseline 155.59 to 130.29 mm Hg
( 25.29 mm Hg) at the end of 12 weeks of treatment
with bisoprolol (SD: 13.22; p<0.05). Similarly, there was
signiﬁcant reduction in DBP ( 14.14 mm Hg) after the
12 week of treatment (SD: 7.67; p<0.05). The mean HR
was also found to be signiﬁcantly reduced from 85.34 to
73.28 ( 12.06) beats per minute after the treatment
(SD: 6.15; p<0.05) (table 3).
Metabolic parameters
Table 4 highlights the baseline and 12-week data of the
patients enrolled and followed up in the BRIGHT study.
Subgroup analysis was done for smokers and younger
hypertensive patients on bisoprolol. Although the overall
Table 2 Demography and vital parameters at baseline
Parameter N (%) or mean±SD
Age (years) 51.7569.8
Body mass index (kg/m
2) 25.4463.8
Heart rate (beats per minute) 85.3269.14
Systolic blood pressure (mm Hg) 155.59611.82
Diastolic blood pressure (mm Hg) 95.6666.95
Men 1440 (66.64)
Women 721 (33.36)
Smokers 430 (19.9)
Non-smokers 1731 (80.1)
Table 3 Haemodynamic parameters at various time points during the study
Visit schedule
SBP (mm Hg) DBP (mm Hg) HR (beats per minute)
Mean±SD Mean±SD Mean±SD
Baseline 155.59611.82 95.6666.95 85.3269.14
2 weeks 144.44612/07 89.2566.65 79.3567.98
4 weeks 138.18612.01 85.4766.23 76.3567.48
8 weeks 133.54611.22 83.0465.77 74.3266.52
12 weeks 130.29610.87 81.5265.23 73.2866.33
Change at 12 weeks from
baseline (%)
 25.29 ( 16.26)  14.14 ( 14.78)  12.05 ( 14.12)
p Value for all parameters <0.05.
DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.
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Bisoprolol as initial therapy in hypertensionresponse rates in smokers (96.75%) and non-smokers
(94.17%) were similar (p¼0.275), a higher number of
smokers responded to bisoprolol within 2 weeks (45.35%
vs 39.17%). Furthermore, smokers had a greater reduc-
tion in HR at the end of 12 weeks ( 13.79 vs  11.99 beats
per minute; p<0.05, table 5).
Similarly, younger patients (age <50 years) showed
a greater reduction in SBP/DBP ( 25.81/ 14.31 vs
 24.53/ 13.67 mm Hg; p<0.05, table 6).
Compliance
About 98.76% of patients were compliant, deﬁned as
those consuming more than 80% of tablets as recom-
mended by the treating physician. BP was found to be
controlled in 1622 (80.9%) patients at the dose of 5 mg/
day. In patients, in whom control was achieved, an
average of 33 days was required to reach the target BP of
<140 and 90 mm Hg.
Adverse events
During the study period, 41 (1.9%) patients reported
mild AEs, which mainly included dizziness, headache,
fatigue, nausea and vomiting. No patient developed
any serious AE. Treatment withdrawal was not requested
by any patients nor deemed required by any of the
physicians.
DISCUSSION
The initial drug management of HTN is a contentious
issue. The Report of the Joint National Committee on
detection, evaluation and treatment of high BP also
recommends b blockers as one of the initial antihyper-
tensive agents.
15 b Blockers have become one of the ﬁrst
choice drugs for antihypertensive therapy in various
countries, unless there are any clinical conditions
contraindicating their use. Recently, there has been
a consensus paper published on ‘The role of b blockers
in the management of HTN: an Asian perspective’.
16
This review found that b blockers are still one of the ﬁrst-
line antihypertensive drugs in many Asian countries.
From the old concept of managing HTN by A or B+ C
or D (initiation by either ACE inhibitor/angiotensin II
receptor blocker (ARBs) or a b blocker and addition of
either calcium channel blocker (CCB) or a diuretic in
case of monotherapy failure), we have come a long way
where data have proven all drug classes to be therapeu-
tically equivalent. This has also been proposed by
European Society of Cardiology - European Society of
Hypertension (ESC-ESH) reappraisal, 2009. Thus, it is
imperative that any class proposed to be ﬁrst-line anti-
hypertensive should be equally effective in clinically
differing subgroups of hypertensive patients.
17 18 While
initiating a b blocker in hypertensive patient, physicians
should make a choice based on effective lowering of BP
to a target of 140/90 mm Hg, protection over 24 h,
selectivity to b-1 blocker, metabolism independent of
CYP2D6, balanced clearance (eg, half liver/half kidney)
and prevention of ‘new-onset’ heart failure and coronary
events.
Table 4 Change in metabolic parameters during the treatment with bisoprolol
Parameter At baseline
At the end
of follow-up
Average difference
from baseline
Fasting blood sugar (mg/dl) 100.9619.2 95.1617.2  5.8
Postprandial blood glucose (2-h after food; mg/dl) 140.92627.49 132.59620.21  8.32
Total cholesterol (mg/dl) 194.7622.0 176.2669.2  18.5
Triglycerides (mg/dl) 166.5644.3 153.5653.3  13
Low-density lipoprotein (mg/dl) 120.3638.7 110.2627.5  10.1
High-density lipoprotein (mg/dl) 43.6620.6 46.2629.4 2.6
Serum creatinine (mg/dl) 0.9760.22 0.9360.20  0.04
Creatinine clearance (ml/min) 94.5623.08 92.58623.03  1.98
The values are represented as mean6SD, and there was no deterioration in any of the measured parameters as per paired t test.
For all the parameters p<0.05, except creatinine clearance (p¼0.09).
Table 5 Change in haemodynamic parameters in smokers and non-smokers, expressed as mean6SD
Parameter SBP DBP HR
Visit schedule Smoker Non-smoker Smoker Non-smoker Smoker Non-smoker
Baseline 156.2612.22 155.34611.71 95.6467.26 95.6566.84 85.6469.07 85.2569.17
2 weeks 146.06612.65 145.15632.32 89.4066.87 89.03466.48 79.8768.58 79.76618.59
4 weeks 139.39612.65 137.82611.87 85.5266.29 85.3266.12 76.5566.88 76.3167.65
8 weeks 134.49612.13 133.27611.01 82.8765.73 83.0365.67 74.1066.64 74.3866.38
12 weeks 130.37611.64 130.26610.74 81.5964.85 81.5365.33 72.6666.20 73.4266.38
Change in SBP at
12 weeks versus baseline
 25.82  25.07  21.4  20.91  13.73*  11.99
*p Value <0.05.
DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.
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Bisoprolol as initial therapy in hypertensionIn our study, response rate of 96.44% was achieved (BP
#140 mm Hg and 90 mm Hg) at the end of 12 weeks
treatment with a median dose of 5 mg/day of bisoprolol.
Although a small percentage of the patients did not
respond to bisoprolol, this number was lower (3.56%)
compared with other therapies.
19 In our study subgroups
as well, the reduction in BP was signiﬁcant, irrespective
of age, gender, smoking status, body mass index, HR and
baseline BP.
It is noteworthy to mention that all the therapeutic
classes have some typical ‘class-related’ side effects.
While ACE inhibitors are known to cause cough, CCBs
can cause pedal oedema, diuretics can cause electrolyte
imbalance, non-selective b blockers can cause AE such as
fatigue, depression, impaired exercise tolerance, sexual
dysfunction and asthma attacks.
20 Although b blockers
have their efﬁcacy proven for controlling BP and HR,
their effect on blood glucose, cholesterol and quality of
life has always been questioned. Bisoprolol, one of the
highest b-1 selective b blocker, reduces BP and HR and is
largely devoid of these side effects.
21e28
In the BRIGHT study, we found favourable changes in
the levels of metabolic and renal parameters. There was
a reduction in the glucose level (fasting blood sugar level
and postprandial blood sugar level) and improvement in
lipid proﬁle (total cholesterol, triglycerides, low-density
lipoprotein and high-density lipoprotein) at the end of
bisoprolol treatment. However, we suggest that these
changes may not be ascertained to bisoprolol therapy as
other confounding factors (reducing salt intake, alcohol
avoidance, multifactorial diet control, weight reduction,
tobacco cessation, physical exercise and stress manage-
ment) were not captured.
29e31
This is the ﬁrst study, to our knowledge, to demon-
strate the efﬁcacy and tolerability of bisoprolol in large
number of Indian patients in real world scenario. The
BRIGHT study also conﬁrms the consistency of thera-
peutic efﬁcacy of bisoprolol even after 25 years of its
approval to be used in the management of HTN.
Although this was a large observational study that
added signiﬁcantly to the efﬁcacy and safety of a b-1
selective b blocker, it could not answer clearly the
difference of using this drug in patients with probably
high epinephrine and nor-epinephrine levels (smoker
and younger patients) compared with the other group.
This study being an open-label study, the possibility
of placebo effect should be considered. In an analysis
of 354 randomised studies, it was found that single
drug given at full dose will cause average reduction in
9.1 mm Hg SBP and 5.5 mm Hg DBP.
32 However, we
would like to draw attention towards comparative
study of atenolol and nebivolol. In this study for
6 months, SBP reduced from 160.1361.62 mm Hg
to 118.9360.87 mm Hg in atenolol arm and from
159.9361.62 mm Hg to 116.7360.91 mm Hg in nebi-
volol. Similar responses were observed with DBP and
HR.
33 Thus, whether Indian patients are highly respon-
sive to b blockers or there is contribution by placebo
effect needs be investigated further.
This study reﬂects the real-life scenario, which is often
missed out in well-designed randomised studies. The
changes in metabolic parameters are unlikely to be
related to bisoprolol, as it was found to be ‘metabolically
neutral’ in previous studies.
34 35 These metabolic
changes would suggest signiﬁcant improvement in the
lifestyle conditions; which could not be measured by
the given study design. Although bisoprolol is found to
be an effective drug in varying clinical situations, we
would still suggest a prospective randomised controlled
study of longer duration, adequately powered to measure
metabolic and renal outcomes as primary end points.
CONCLUSION
The BRIGHT study showed that bisoprolol can be used
effectively as ﬁrst-line treatment for the patients diag-
nosed with stage I essential HTN.
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